BriaCell Therapeutics Corp.
BCTXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeBriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. With a market capitalization of $32.6M, it sits in micro-cap territory. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials.
Market Cap
$32.6M
Beta
1.54
P/E (TTM)
—
P/E (Fwd)
-9.62
EPS (TTM)
$-0.87
EPS (Fwd)
$-0.39
ROE
-175.3%
ROA
-90.8%
Cash
$22.8M
Total Debt
$0
Free CF
-$20.0M
52W Change
-53.7%
Annual Financials
Cash vs Debt
Where BCTX stands vs its 150-day and 200-day moving averages
As of the July 14, 2026 close, BCTX finished 21.87% below its 150-day moving average ($4.80) and 40.94% below its 200-day moving average ($6.35). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BCTX overbought or oversold?
At the July 14, 2026 close, BCTX's RSI(14) was 70.1, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
BriaCell Therapeutics Corp. reports $22.8M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$20.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -175.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
BriaCell Therapeutics Corp.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing BCTX.